Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III study of MD-712 (treprostinil) in pulmonary hypertension
jRCT2031240628Phase 3Active, not recruiting
- Sponsor
- Mochida Pharmaceutical Co., Ltd.
- Start
- Feb 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of treprostinil in pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease (PH-ILD), pulmonary hypertension (PH) and 4 more, sponsored by Mochida Pharmaceutical Co., Ltd. Primary endpoint: Rate of change in pulmonary vascular resistance index. Started Feb 2025; status: active, not recruiting.
02
Drugs
treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)pulmonary hypertension associated with interstitial lung disease (PH-ILD)pulmonary hypertension (PH)Plexogenic Pulmonary ArteriopathyHeritable Pulmonary Arterial Hypertension (HPAH)
Beyond the preview
Go deeper on jRCT2031240628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240628.